Basket cover image
15 handpicked stocks

Next-Generation Drug Delivery Systems

This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated today | Published at July 18

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

PODD

Insulet Corporation

PODD

Current price

$321.27

Develops wearable insulin delivery systems that simplify administration for diabetic patients.

RANI

Rani Therapeutics Holdings Inc

RANI

Current price

$0.53

Creates oral delivery platforms for biologics that traditionally require injection.

AVDL

AVADEL PHARMACEUTICALS-ADR

AVDL

Current price

$13.69

Focuses on extended-release drug delivery technologies for improved patient compliance.

About This Group of Stocks

1

Our Expert Thinking

The FDA's approval of GSK's pre-filled Shingrix vaccine highlights a significant industry shift toward simplified drug delivery. Companies developing user-friendly delivery systems like pre-filled syringes, wearable pumps, and needle-free options are gaining valuable competitive advantages as pharmaceutical giants seek to differentiate their products.

2

What You Need to Know

This group includes companies across the drug delivery value chain, from oral alternatives to injectable medications to sustained-release implants. These innovations aim to reduce healthcare provider burden, minimize administration errors, and improve patient compliance, potentially leading to better clinical outcomes.

3

Why These Stocks

These companies were selected based on their position to benefit from the pharmaceutical industry's accelerating adoption of advanced delivery technologies. With proprietary platforms that transform complex treatments into simplified formats, they represent a tactical opportunity in response to recent regulatory validation.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+449.86%

Group Performance Snapshot

449.86%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 449.86% over the next year.

12 of 15

Stocks Rated Buy by Analysts

12 of 15 assets in this group are rated Buy by professional analysts.

18.2% vs 4%

Group Growth vs Bank interest

This group averaged a 18.2% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💉

Riding the Patient-First Healthcare Wave

Healthcare is rapidly shifting toward more patient-friendly treatments, and these companies are at the forefront. The FDA's recent approval of GSK's pre-filled Shingrix vaccine signals growing demand for simpler delivery solutions.

🔬

Pharmaceutical Giants Are Shopping

Major pharma companies are actively seeking innovative delivery systems to differentiate their products in crowded markets. This creates valuable partnership and acquisition opportunities for these specialized firms.

📈

The Compliance Advantage

These technologies solve a critical healthcare challenge: patient compliance. By making treatments easier to administer correctly, these companies aren't just improving outcomes—they're creating potentially recurring revenue streams.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Uncle Sam's Semiconductor Stake

Uncle Sam's Semiconductor Stake

The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.

View stocks
The Cybersecurity Consolidation Wave

The Cybersecurity Consolidation Wave

Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.

View stocks
American Chipmakers: A Tariff-Driven Shift

American Chipmakers: A Tariff-Driven Shift

President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.